Our Q4 Report is out. CEO: "We enter the new Quarter with renewed energy following the announcement in February, of ‘First Patient First Visit’ for our Phase IIa Tourette study" news.cision.com/asarina-pharma…

"Topline results for our phase IIa study in #tourettes in Copenhagen are still expected Q1 2023 and the study remains fully funded" CEO Peter Nordkild in our 2021 Annual Report asarinapharma.com/investors/fina…

"A safe treatment for Tourette syndrome that reduced tics with no side effects would be a life-changing, life-saving intervention. In Q1 we have kept steadfastly to the recruitment goals in our phase IIa Tourette study" CEO. Read Q1 Report HERE asarinapharma.com/investors/fina…

Our Q2 Report 2022 shows continued progress in our Phase II trial of #Sepranolone for #Tourette. With an unexpectedly low drop-out rate (under 5%) + more than two thirds of patients recruited we expect topline results by the end of Q1 2023. asarinapharma.com/wp-content/upl… #finanstwitter

An extensive new preclinical study reconfirms the central role Allopregnanolone plays in Tourettes and OCD, & how Sepranolone modulates its negative effects. "This powerfully extends the Translatability of our data" CEO. news.cision.com/asarina-pharma… #finanstwitter

We have now reached full recruitment on our landmark Phase IIa #tourettes study! 28 patients enrolled, last patient randomized Oct 14. The dropout rate remains unexpectedly low and topline results are still expected end of Q1 2023. news.cision.com/asarina-pharma… #finanstwitter

"We’d like to thank all our partners, investors and stakeholders for sharing our journey in 2022 and wish you a warm holiday season with your loved ones & a happy 2023" CEO Peter Nordkild, Asarina Pharma.

We are pleased to announce Last Patient Last Visit in our Phase IIa clinical study in #tourettes. The dropout rate in the study remained unexpectedly low throughout. CEO Peter Nordkild: "we look forward to releasing findings at the end of March '23." asarinapharma.com/press-releases/

Our YE Report 2022 covers Sepranolone & our Phase IIa trial for #tourettesyndrome. Topline results will be released at the end of March 2023. CEO: "if Sepranolone meets its clinical endpoints, its proven safety profile could set it apart" .asarinapharma.com/investors/fina… #finanstwitter

We report positive results from our Phase IIa study of Sepranolone in #TouretteSyndrome. CEO Peter Nordkild: "these results offer encouraging evidence of a safer, more tolerable treatment for patients living with TS" news.cision.com/asarina-pharma… #Neurology #finanstwitter

On Thurs' 13 April CEO Peter Nordkild is interviewed by Redeye on our positive #Tourette study results. "This is an exciting step towards Sepranolone ultimately becoming a safer, first-line pharmaceutical treatment for Tourette, with no no off-target effects." #finanstwitter

CEO Peter Nordkild talks about our positive Phase IIa results in Tourette Syndrome and how Sepranolone achieved good efficacy in tic reduction, improved patient quality of life and no off-target CNS side effects. redeye.se/research/89378… #finanstwitter

On April 20 (1800-2000) our CEO Peter Nordkild presents our positive Phase IIa results on Sepranolone for the treatment of #tourettesyndrome at the Redeye Investor Forum, Gothenburg. redeye.se/events/870525/… #finanstwitter

Watch CEO Peter Nordkild discuss Asarina Pharma's positive results for its Phase IIa study in Tourette syndrome with Direkt Studios. Watch at 1 min 33 secs. youtube.com/watch?v=MayM47… #Tourette #finanstwitter

Join CEO Peter Nordkild on THURS' 20 APRIL as he presents our positive Phase IIa results in #Tourette syndrome at the Redeye Investor Forum in Gothenburg. Register here. redeye.se/events/870525/…

CEO Peter Nordkild explains our positive #Tourettes results in our Phase IIa study at the Redeye AB Investor Forum in Gothenburg - from tic reduction to safety to improved quality of life. redeye.se/video/event-pr… #finanstwitter #tourettesyndrome

“The side effects with antipsychotics are so heavy that very few #Tourette patients can keep taking them for long. Sepranolone gives us a safer option" Consultant Neurologist Dr. Heidi Biernat. Read the full interview here. asarinapharma.com/tourette-syndr…

Could our endogenous compound Sepranolone become a new safer, more tolerable pharmaceutical treatment for #Tourettes that reduces Tics and improves quality of life? Our 2022 Annual Report with Clinical Neurologist Dr Heidi Biernat is here asarinapharma.com/investors/fina… #finanstwitter

Our Phase IIa results in Tourette demonstrated positive tic reduction, improved quality of life and no off-target CNS side effects. Meet Asarina Pharma CEO Peter Nordkild at #bio2023 June 5 -8. REGISTER here: bio.org/events/bio-int… #tourette #movementdisorders #Neurology

Our H1 2023 Report has positive results for our safe compound for #Tourette, Sepranolone, in our Phase IIa study & the new data at scientific, clinical and business events. CEO Peter Nordkild: "We've seen keen interest and awareness" asarinapharma.com/all_news/asari…